EPKINLY Drug Profile

✉ Email this page to a colleague

Summary for Tradename: EPKINLY

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for EPKINLY

Recent Clinical Trials for EPKINLY

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Genmab	Phase 3
AbbVie	Phase 3
City of Hope Medical Center	Phase 2

See all EPKINLY clinical trials

Pharmacology for EPKINLY

Mechanism of Action	CD20-directed Antibody Interactions CD3 Receptor Agonists CD3-directed Antibody Interactions Cytochrome P450 Inhibitors
Physiological Effect	Increased Cytokine Activity
Established Pharmacologic Class	Bispecific CD20-directed CD3 T Cell Engager

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for EPKINLY Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for EPKINLY Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for EPKINLY Derived from Patent Text Search

No patents found based on company disclosures

EPKINLY Market Dynamics, Revenue Outlook, Competition, and Patent Position

Last updated: November 2, 2026

EPKINLY, known as EPKINLY in the U.S. and TEPKINLY in the European Union, is AbbVie and Genmab’s subcutaneous epcoritamab-bysp CD20xCD3 bispecific antibody. Its commercial trajectory is driven by expansion from heavily pretreated diffuse large B-cell lymphoma (DLBCL) into follicular lymphoma (FL), broader use before CAR-T therapy, outpatient administration, and competition from CAR-T therapies and other CD20-directed bispecific antibodies.

The drug received U.S. accelerated approval for relapsed or refractory DLBCL after at least two systemic therapies in May 2023 and accelerated approval for relapsed or refractory FL after at least two lines of therapy in June 2024.[1][2] EPKINLY has a differentiated delivery profile because it is administered subcutaneously rather than by intravenous infusion.

What is EPKINLY and how does its mechanism support commercial adoption?

EPKINLY is a CD20xCD3 T-cell-engaging bispecific antibody. It binds CD20 on malignant B cells and CD3 on T cells, producing immune-mediated B-cell killing.

Its principal commercial advantages are:

Subcutaneous administration.
A fixed-dose regimen after step-up dosing.
Activity in aggressive and indolent B-cell lymphomas.
Use without patient-specific cell manufacturing.
Potential administration in outpatient settings after initial treatment.
Compatibility with treatment sequencing before or after CAR-T therapy.

The main limitation is cytokine release syndrome (CRS), which requires step-up dosing, premedication, monitoring, and risk-management procedures. Neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome, is also clinically relevant.[1]

EPKINLY dosing and treatment logistics

The U.S. label uses step-up dosing to reduce CRS risk. The initial schedule is administered weekly, followed by less frequent maintenance dosing depending on treatment cycle and indication. The regimen creates an early monitoring burden but reduces the recurring infusion-center time associated with intravenous bispecific antibodies.

The subcutaneous route is commercially important in three areas:

It may reduce chair time and infusion capacity requirements.
It supports community oncology administration after initial monitoring.
It may improve convenience relative to intravenous bispecific antibodies.

These advantages do not eliminate the need for CRS management. Treatment centers must still establish protocols for step-up dosing, observation, hospitalization, and access to tocilizumab when clinically indicated.

What FDA approvals and exclusivity periods apply to EPKINLY?

Milestone	Date	Commercial significance
U.S. FDA accelerated approval in relapsed/refractory DLBCL after at least two lines	May 19, 2023	Initial U.S. launch
U.S. FDA accelerated approval in relapsed/refractory FL after at least two lines	June 26, 2024	Expands addressable patient population
European Commission authorization for TEPKINLY in relapsed/refractory DLBCL	2023	Establishes European commercial market
European authorization in relapsed/refractory FL	2024	Adds an indolent lymphoma indication
U.S. reference-product biologic exclusivity	Generally 12 years from first licensure under the BPCIA	Earliest statutory biosimilar approval barrier is approximately May 2035, subject to statutory interpretation and product-specific regulatory treatment

The DLBCL and FL approvals were accelerated approvals based on response data. Continued marketing depends on confirmatory evidence demonstrating clinical benefit.[1][2] The approval structure creates regulatory risk if confirmatory trials fail to verify benefit, although EPKINLY’s expansion into FL reduces dependence on a single indication.

EPKINLY also benefits from orphan-drug protections for certain lymphoma indications. Orphan exclusivity is indication-specific and can restrict approval of the same drug for the same disease for seven years from approval, subject to statutory exceptions. Orphan exclusivity does not prevent all competing products from entering the broader lymphoma market.

How large is the EPKINLY market opportunity?

The commercial opportunity spans two different markets.

Relapsed or refractory DLBCL

DLBCL is a high-value market with substantial unmet need after failure of first-line chemoimmunotherapy and subsequent treatment. Patients may receive:

Salvage chemotherapy followed by autologous stem-cell transplant.
CAR-T therapy.
Polatuzumab-based regimens.
Bispecific antibodies.
Palliative or lower-intensity therapy for patients unable to receive intensive treatment.

EPKINLY competes most directly in later-line treatment, but its long-term opportunity depends on movement into earlier lines. Earlier-line treatment would materially increase patient volume and treatment duration, but it would also bring direct competition from CAR-T therapy, other bispecific antibodies, and established chemoimmunotherapy.

Relapsed or refractory FL

FL creates a broader and potentially more durable market than late-line DLBCL. Patients may receive multiple lines of treatment over several years, creating recurring-treatment potential.

The FL opportunity has four commercial advantages:

A larger patient population than third-line DLBCL.
Longer treatment courses for responding patients.
Greater use in patients unsuitable for CAR-T.
Potential for use in community oncology after treatment centers gain experience with CRS management.

The principal constraint is that FL treatment is increasingly crowded. Mosunetuzumab, CAR-T products, lenalidomide-based regimens, PI3K-pathway therapies, and other CD20-directed approaches compete for the same treatment decisions.

What is the financial trajectory for EPKINLY?

EPKINLY’s financial trajectory is in the early growth phase rather than the mature-product phase. The sequence of commercial drivers is:

Initial DLBCL launch in 2023.
Increasing treatment-center activation and physician familiarity.
FL approval in 2024.
Expansion of community-based administration.
Earlier-line clinical development.
International reimbursement and label expansion.

AbbVie and Genmab report EPKINLY-related economics through their collaboration and product disclosures rather than through a fully independent public income statement for every market. AbbVie records product sales, while Genmab receives royalties and collaboration economics under the companies’ agreement.[3][4]

Revenue drivers

The strongest near-term revenue variables are:

Number of activated treatment centers.
Share of eligible DLBCL patients treated with a bispecific antibody.
FL uptake after the 2024 approval.
Duration of therapy among responders.
Conversion from academic centers to community oncology.
Reimbursement for subcutaneous administration.
Use before or after CAR-T.
Results from earlier-line studies.

Revenue constraints

Revenue growth can be limited by:

CRS-related treatment logistics.
Physician preference for CAR-T in eligible patients.
Competition from glofitamab and mosunetuzumab.
Limited duration of treatment in refractory DLBCL.
Payer controls in a crowded lymphoma class.
Confirmatory-trial requirements associated with accelerated approval.
Potential price pressure as multiple bispecific antibodies enter the market.

The FL indication is strategically important because it can increase treatment duration and diversify revenue away from a late-line DLBCL population with high mortality and short treatment windows.

How does EPKINLY compare with competing lymphoma drugs?

Product	Company	Target or modality	Administration	Main competitive issue
EPKINLY/TEPKINLY	AbbVie/Genmab	CD20xCD3 bispecific	Subcutaneous	CRS management; later-line positioning
LUNSUMIO	Roche	CD20xCD3 bispecific	Intravenous	FL positioning; infusion burden
COLUMVI	Roche	CD20xCD3 bispecific	Intravenous	DLBCL efficacy and step-up regimen
CAR-T therapies	Multiple companies	Autologous cellular therapy	One-time cellular treatment	Potentially durable responses; manufacturing and referral burden
POLIVY	Roche	CD79b antibody-drug conjugate	Intravenous combination	Earlier-line and combination competition
Rituximab-based regimens	Multiple companies	Anti-CD20 antibody	Intravenous or subcutaneous depending on product	Established reimbursement and physician familiarity

EPKINLY’s principal product-level differentiation is subcutaneous administration. Its principal clinical challenge is proving that convenience and efficacy justify selection against CAR-T and competing bispecific antibodies.

Direct head-to-head evidence remains limited. Cross-trial comparisons are unreliable because studies differ in patient risk, prior CAR-T exposure, disease burden, response assessment, and follow-up duration.

What is the competitive landscape for CD20-directed bispecific antibodies?

The market is moving from a single-product innovation category toward a multi-product class.

DLBCL competition

In DLBCL, EPKINLY competes with glofitamab, which has an intravenous fixed-duration treatment approach, and with CAR-T products such as YESCARTA, BREYANZI, and ABECMA in relevant treatment sequences. Treatment choice depends on:

Eligibility for cellular therapy.
Speed of disease control.
Referral and manufacturing timelines.
Need for outpatient treatment.
Expected durability.
Patient frailty and comorbidities.
Provider experience with CRS.

EPKINLY can benefit when CAR-T is unavailable, clinically unsuitable, or delayed. It may also compete as an off-the-shelf option after CAR-T failure.

FL competition

In FL, EPKINLY competes against mosunetuzumab and CAR-T products including KIMOPTRI and BREYANZI in applicable settings. FL treatment decisions are more sensitive to treatment duration, quality of life, outpatient practicality, and cumulative toxicity than to short-term response alone.

Subcutaneous administration can support EPKINLY’s position in FL, but long-term comparative data and duration of response will determine whether the product achieves preferred status.

What patent and regulatory rights protect EPKINLY?

EPKINLY is a biologic and is not protected through the small-molecule Orange Book system in the same manner as a conventional tablet or capsule. Its regulatory reference-product information is associated with FDA biologics records and the Purple Book framework.

The relevant protection layers include:

The biologic reference-product exclusivity period.
Patent claims covering epcoritamab molecules and antibody sequences.
Patent claims covering CD20xCD3 binding architecture.
Formulation and stability claims.
Subcutaneous delivery and dosing-regimen claims.
Manufacturing and cell-line claims.
Method-of-use claims for B-cell malignancies.
Orphan-drug exclusivity for specific indications.

A biosimilar applicant must address applicable patents and regulatory exclusivity under the Biologics Price Competition and Innovation Act. Biosimilar litigation risk is usually assessed through the statutory patent-exchange process rather than a conventional Hatch-Waxman Paragraph IV filing.

When could EPKINLY face biosimilar or generic competition?

A conventional generic version is not expected because EPKINLY is a biologic. The relevant later-entry threat is a biosimilar or interchangeable biosimilar.

The earliest practical U.S. biosimilar timing is shaped by:

The May 2023 first-licensure date.
Twelve years of reference-product exclusivity.
Patent expiration dates.
Patent litigation and settlement terms.
FDA review and interchangeability considerations.
Manufacturing complexity and clinical comparability requirements.

On a statutory reference-product-exclusivity basis, the earliest FDA approval timing would be approximately 2035. Commercial launch could occur later if valid patents, settlements, or regulatory delays extend effective protection.

Are Paragraph IV challenges relevant to EPKINLY?

No conventional Paragraph IV filing applies to EPKINLY in the same way that it applies to an approved small-molecule drug under an abbreviated new drug application. Biosimilar applicants instead use the BPCIA framework, including patent-information exchange and potential declaratory or infringement litigation.

The absence of a conventional Paragraph IV challenge does not mean low entry risk. The critical questions are whether AbbVie and Genmab have enforceable composition, formulation, method-of-use, and manufacturing claims, and whether a biosimilar applicant can design around those claims.

What manufacturing and intellectual-property barriers affect EPKINLY?

Manufacturing is a meaningful barrier because EPKINLY requires:

Mammalian-cell expression.
Precise heavy-chain and light-chain pairing.
Controlled bispecific assembly.
High-purity purification.
Consistent subcutaneous formulation.
Control of aggregation and immunogenicity.
Validated potency assays for two antigen-binding functions.

The most commercially relevant patent claims are likely to involve antibody sequence and structure, production-cell systems, purification, formulation stability, and treatment regimens. Manufacturing complexity supports pricing power and delays practical biosimilar substitution, even after regulatory exclusivity expires.

What licensing deal governs EPKINLY economics?

Genmab and AbbVie entered into a strategic collaboration covering the development and commercialization of epcoritamab. AbbVie leads commercialization in many markets, while Genmab retains collaboration economics through royalties and other financial rights.[3][4]

The arrangement distributes risk and capital requirements:

AbbVie contributes global commercial infrastructure and oncology sales capacity.
Genmab receives milestone and royalty economics without funding the entire commercial platform.
Both companies benefit from label expansion.
Revenue growth for Genmab is tied to AbbVie’s product execution and reporting.

This structure makes EPKINLY strategically important to both companies, but the reported financial impact differs. AbbVie captures product revenue, while Genmab captures collaboration revenue and royalties.

What litigation and settlement risks affect EPKINLY?

Publicly visible risk is more likely to emerge through future biosimilar patent litigation than through a current small-molecule-style Paragraph IV case. Potential disputes may involve:

Antibody sequence claims.
Bispecific architecture.
Cell-line and manufacturing methods.
Formulation claims.
Subcutaneous dosing schedules.
Treatment of DLBCL or FL.
Patent-term adjustment and expiration calculations.

Settlement agreements could establish a delayed biosimilar entry date, license terms, or geographic restrictions. No settlement should be assumed without a public court filing, company disclosure, or regulatory record.

What generic launch scenarios exist for EPKINLY?

Early biosimilar entry scenario

A biosimilar sponsor challenges core composition and method-of-use patents, wins or narrows litigation, and launches near the end of the 12-year reference-product exclusivity period. Price erosion would depend on interchangeability, payer adoption, and the number of competing biosimilars.

Delayed-entry scenario

AbbVie and Genmab enforce composition, formulation, and manufacturing patents and settle with a launch date after the earliest statutory period. This scenario preserves higher net pricing but may still produce contracting pressure before biosimilar launch.

Indication-limited entry scenario

A biosimilar enters for a nonprotected indication while EPKINLY retains exclusivity or patent protection in another indication. This could produce partial competition rather than immediate erosion across the entire product.

How strong is the EPKINLY commercial position?

EPKINLY has a strong launch platform but an evolving long-term position.

Strengths

Subcutaneous administration.
Two major lymphoma indications.
Off-the-shelf availability compared with CAR-T.
Partnership with AbbVie.
Genmab’s bispecific-antibody expertise.
Potential for earlier-line expansion.
Applicability to patients unable to receive cellular therapy.

Weaknesses

CRS and step-up dosing requirements.
Accelerated-approval obligations.
Intense competition from other bispecifics.
Limited head-to-head evidence.
Late-line DLBCL treatment duration.
Dependence on oncology-center operational readiness.
Future biosimilar and patent litigation risk.

The highest-value strategic question is whether EPKINLY can move beyond later-line treatment into earlier DLBCL and FL settings. Earlier-line success would expand patient volume, improve treatment duration, and support a longer commercial life before biosimilar entry.

Key Takeaways

EPKINLY is a subcutaneous CD20xCD3 bispecific antibody marketed by AbbVie and Genmab.
U.S. approval began with late-line DLBCL in May 2023 and expanded to late-line FL in June 2024.
FL provides the broader recurring-treatment opportunity, while DLBCL supports demand among patients needing an off-the-shelf alternative to CAR-T.
The main competitive advantages are subcutaneous delivery, fixed-dose treatment, and lack of individualized manufacturing.
The main risks are CRS logistics, competing bispecific antibodies, CAR-T substitution, accelerated-approval requirements, and future biosimilar litigation.
EPKINLY is a biologic, so biosimilar entry under the BPCIA framework is more relevant than a conventional Paragraph IV generic challenge.
The earliest statutory U.S. reference-product exclusivity timing is approximately 2035, based on the May 2023 first-licensure date.
Earlier-line expansion is the main factor that could materially improve the product’s long-term revenue trajectory.

FAQs

Is EPKINLY a CAR-T therapy?

No. EPKINLY is an off-the-shelf bispecific antibody that redirects T cells to CD20-positive B cells. CAR-T therapy requires collection, genetic modification, manufacturing, and reinfusion of the patient’s cells.

Is EPKINLY approved for first-line lymphoma treatment?

No. The cited U.S. approvals cover relapsed or refractory DLBCL after at least two systemic therapies and relapsed or refractory FL after at least two lines. Earlier-line use requires separate regulatory approval.

Does EPKINLY require hospitalization?

Not for every patient or dose. Step-up dosing and CRS monitoring may require observation or hospitalization based on institutional protocols, patient risk, symptoms, and the timing of administration.

Which company owns EPKINLY?

EPKINLY is commercialized through the AbbVie-Genmab collaboration. AbbVie has major commercial responsibilities, while Genmab receives collaboration economics, including royalties and other payments under the agreement.

Will EPKINLY face biosimilar competition?

Yes, biosimilar competition is a long-term possibility. The timing will depend on the 12-year reference-product exclusivity period, patent validity, litigation outcomes, settlement terms, and FDA review.

References

U.S. Food and Drug Administration. (2023). EPKINLY prescribing information. FDA.
U.S. Food and Drug Administration. (2024). FDA grants accelerated approval to epcoritamab-bysp for relapsed or refractory follicular lymphoma. FDA.
AbbVie Inc. (2024). Annual report 2023. AbbVie.
Genmab A/S. (2024). Annual report 2023. Genmab.
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.
U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, §7002.

More… ↓

⤷ Start Trial